Document is current

Article History

Received: 1 May 2021

Accepted: 11 June 2021

First Online: 24 June 2021

Declarations

:

: The procedures followed were in accordance with the precepts of Good Clinical Practice and the declaration of Helsinki. The study was approved by the respective local ethical committees on human experimentation of each institution, after previous approval by the coordinating center (University of L’Aquila, Internal Review Board protocol number 32865, approved on July 24th, 2018).

: Not applicable.

: Dr Sebastiano Buti received honoraria as speaker at scientific events and advisory role by Bristol-Myers Squibb (BMS), Pfizer; MSD, Ipsen, Roche, Eli-Lilly, AstraZeneca and Novartis. Dr. Melissa Bersanelli received research funding by Roche, Seqirus, Pfizer and Novartis, personal fees as speaker/consultant by AstraZeneca, Novartis, Pfizer, BMS. Dr Raffaele Giusti received speaker fees and grant consultancies from AstraZeneca and Roche. Dr Maria G Vitale received speaker fees, grant consultancies and travel support from BMS, Ipsen, Novartis, Pfizer, Astellas, Jansen and Pierre-Fabre. Dr Alessandro Russo received grant consultancies from AstraZeneca and MSD. Dr Francesco Spagnolo received speaker fees and grant consultancies from Roche, Novartis, BMS, MSD, Pierre-Fabre, Sanofi, Merck and Sunpharma. Paolo A. Ascierto has/had a consultant/advisory role for Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Array, Merck Serono, Pierre-Fabre, Incyte, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Takis, Lunaphore, Seagen. He also received research funding from Bristol Myers Squibb, Roche-Genentech, Array, Sanofi and travel support from MSD. Dr David J. Pinato received lecture fees from ViiV Healthcare, Bayer Healthcare and travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, Astra Zeneca; received research funding (to institution) from MSD, BMS. Dr Alessio Cortellini received speaker fees and grant consultancies from Roche, MSD, BMS, AstraZeneca, Novartis, Astellas. All other authors declared no competing interests.